Stock Taper 
Cytek Biosciences develops advanced spectrum flow cytometry systems, reagents, and software for cell analysis, serving biomedical research, clinical, and biopharma markets worldwide.
The Cytek Aurora™ Evo is a high-throughput, automated spectral flow cytometer built on the flagship Aurora, offering advanced multicolor analysis with improved performance, efficiency, and ease of use for complex cell research.
Cytek Biosciences announced its financial results for the first quarter of 2025, reporting a total revenue of $41.5 million, which represents a 7.6% decrease compared to the first quarter of 2024. Citing a challenging macroeconomic backdrop, the company also revised its full-year 2025 revenue guidance to a range of $196 million to $210 million, representing a growth of -2% to 5% over the previous year.
In 2025, Cytek Biosciences made a significant strategic move to enhance its global operational footprint by relocating its European headquarters to a larger facility in Amsterdam and commencing operations at a new manufacturing site in Singapore. This dual initiative is aimed at strengthening the company's presence in the EMEA region, improving supply chain control, increasing manufacturing capacity, and accessing lower-cost production.
Bank of America Corp DE purchased a new position in shares of Cytek Biosciences, Inc. (NASDAQ: CTKB) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 1,315,332 shares of the company's stock, valued at approximately $5,827,000. Bank of America Corp
Overall rating: C
| PEER | PRICE | |
|---|---|---|
 CBLL | $23.69 | COMPARE |
 VREX | $18.46 | COMPARE |
 ANGO | $15.11 | COMPARE |
 KIDS | $22.16 | COMPARE |
 CLPT | $10.89 | COMPARE |
 LAB | $0.74 | COMPARE |
 TMCI | $4.39 | COMPARE |
 ORGO | $1.33 | COMPARE |
